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SUMMARY
The spontaneous occurrence of antibodies against the Sm nuclear antigen is a highly specific marker
for the diagnosis of SLE. We have previously shown that anti-Sm can be elicited by immunization of
SLE-prone mice with purified Sm antigen. In the present study, this autoantibody was induced in
normal mice by a similar immunization protocol. Anti-Sm produced by normal strains was
predominantly IgGl, which is similar to the isotype distribution in Sm-immunized MRL mice, but
unlike the IgG2a-dominated response seen for spontaneous anti-Sm. Anti-Sm raised by immuniza-
tion in most strains recognized epitopes not seen by spontaneous human and murine SLE anti-Sm; of
the eleven normal strains tested, only C3H and AKR, strains from which MRL was partially derived,
responded to these determinants. Further, immunoblot analysis of anti-Sm generated by immuniza-
tion ofMRL and normal mice revealed that the same proteins recognized by spontaneous human and
murine anti-Sm were also seen by these sera. This study shows that an autoantibody highly
characteristic ofSLE can be produced in normal and MRL mice after appropriate immunization, and
that the fine specificity ofsuch experimentally induced antibody can be similar to that ofspontaneous
anti-Sm autoantibodies. The results imply a role for autoimmunization with Sm in the production of
anti-Sm.
INTRODUCTION
Spontaneous production of autoantibodies to the Sm nuclear
antigen is unique to human and canine SLE and to the MRL
mouse strains (Eisenberg, Tan & Dixon, 1978; Tan et al., 1982).
This antigen has been termed a small nuclear ribonucleoprotein
(snRNP) and consists ofa complex of8-10 proteins and uridine-
rich RNAs. In both humans and MRL mice, anti-Sm-contain-
ing sera recognize the protein components of the snRNP
particle. The complexity and polyclonality of this antibody
response imply that anti-Sm production is driven by antigen,
probably the Sm particle itself. Our studies of spontaneous anti-
Sm in the autoimmune MRL mouse strains have provided
evidence that the Sm antigen itself serves as the immunogen in
this response. In vitro production of anti-Sm autoantibodies
requires the continued availability of antigen; moreover, the
magnitude of the response can be enhanced by provision of
Abbreviations: NHu IgG, normal human IgG; MSm, mouse Sm;
RSm, rabbit Sm.
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supplemental antigen to cultures (Cohen & Eisenberg, 1982;
Shores, Eisenberg & Cohen, 1986).
Although anti-Sm can be elicited by immunization in all
MRL mice, this autoantibody occurs spontaneously in only a
minority of such animals. As determined by in vitro precursor
analysis using LPS to stimulate antibody production, indeed,
MRL mice not actively producing anti-Sm lack detectable
precursors by this assay (Cohen et al., 1985). B cells specific for
Sm must exist even in these mice, however, since they can be
expanded and stimulated to antibody production by repeated in
vivo immunization with purified antigen (Shores et al., 1986).
These anti-Sm precursor B cells might possess similar specificity
to the B cells which make spontaneous anti-Sm, or their
products might be reactive to different components of the Sm
immunogen and consequently of less interest than the anti-Sm
antibodies arising in the natural course of murine SLE.
The purpose of the present study was therefore to character-
ize further the nature of anti-Sm produced in Sm-immunized
mice and to determine its relationship to spontaneous anti-Sm.
In addition, as MRL mice have a genetic background which
predisposes them to autoimmune disease, we wished to deter-
mine whether normal mice could generate anti-Sm when
immunized with purified Sm. Our results indicate that normal
mice, as well as MRL mice, were able to produce anti-Sm when
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Figure 1. Induction of anti-Sm antibodies in normal mice. Mice were immunized with the RSm or KLH, and their sera were tested
individually for the presence ofanti-RSm or anti-KLH antibodies by ELISA. Samples were obtained from mice 12 weeks following their first
immunization (at the peak ofthe response). Values represent mean and standard error of four to six mice. MRL/lpr* represents the ELISA
value of a standard pool of sera from unimmunized anti-Sm positive MRL/lpr mice.
immunized with purified rabbit Sm antigen (RSm). The proteins
recognized by anti-Sm antibodies produced by immunization in
both normal and MRL mice were the same as those seen by
spontaneous murine and human SLE anti-Sm. ELISA inhibi-
tion experiments, moreover, showed considerable sharing of
epitopes between spontaneous anti-Sm and anti-Sm experimen-
tally induced in MRL mice. In contrast, only two of eleven
normal strains made anti-Sm that was effectively inhibited by
the SLE anti-Sm. This study indicates that both normal mice
and MRL mice have anti-Sm precursor B cells which resemble
those utilized in the spontaneous anti-Sm response. The fine
specificity of anti-Sm from MRL mice is apparently under non-
MHC-linked genetic control and may be due to background
genes shared with C3H and AKR. In addition, the elicitation by
Sm immunization of anti-Sm with specificity similar to that of
spontaneous anti-Sm constitutes further indirect evidence that
the anti-Sm autoantibodies seen in SLE arise from self-
immunization with the Sm autoantigen.
MATERIALS AND METHODS
Animals
MRL/Mp- + /+ (MRL/+), MRL/Mp-lpr/lpr (MRL/lpr),
C3H, A.CA, A.SW, A.BY, C57BL/10 (B1O), B10.D2, B1O.A,
B10.M, B1O.S, and CBA/J mice were bred at the University of
North Carolina, Chapel Hill. BALB/c, AKR, and (C57BL/
6 x C3H)F1 (B6C3) mice were purchased from Charles River
Breeding Laboratories (Wilmington, MA, U.S.A.). C3H-H-2°
and C3H.SW mice were from the Jackson Laboratory (Bar
Harbor, ME, U.S.A.).
Sm antigen
Sm antigen was prepared from rabbit thymus extract (Pel Freez,
Rogers, AR, U.S.A.) by affinity purification on a column ofIgG
from a patient with high titre anti-Sm (Eisenberg, Klapper &
Cohen, 1983; Bernard, Eisenberg & Cohen, 1985a, 1985b).
Immunization and serum collection
Two to three month old mice were immunized intraperitoneally
(i.p.) weekly for 5 weeks: twice with antigen in complete
Freund's adjuvant (CFA), once with antigen in incomplete
Freund's adjuvant (IFA) and twice with antigen in normal
saline. Groups of four to five mice were immunized with 25 pg of
RSm or keyhole limpet haemocyanin (KLH, Calbiochem, La
Jolla, CA, U.S.A.). Mice were bled from the retro-orbital sinus,
and sera were stored at 40 in the presence of 0-1% NaN3.
ELISA for anti-Sm (Eisenberg, Winfield & Cohen, 1982)
RSm in borate-buffered saline with protease inhibitors (BBS-Pi)
was added to microtitre plates. After 5 hr the plates were non-
specifically coated with BBS-Pi+ BSA + Tween 80. Test sam-
ples, diluted 1/1000 generally, were added to the plates and
allowed to incubate overnight. Total IgG anti-Sm was measured
after adding biotinylated goat anti-mouse IgG (pFc' specific).
To measure IgG subclasses of anti-Sm, rabbit anti-mouse IgG
subclass reagents (Organon Teknika, Malvern, PA) were added,
followed by biotinylated goat anti-rabbit IgG (pFc' specific).
The dilutions of the rabbit anti-mouse subclass reagents gave
comparable optical density (OD) values when tested against
dilutions of myeloma proteins that had been coated directly
onto microtitre plates. Further, the anti-subclass reagents were
tested for specificity and were found to be less than 10% cross-
reactive with inappropriate myeloma proteins. After the bioti-
nylated reagents, avidin alkaline phosphatase was added,
followed by the alkaline phosphatase substrate, paranitrophe-
nyl phosphate. Between each of the steps described above, the
plates were washed five times with BBS. The OD405 was
measured with a microELISA reader. The specificity of anti-Sm
binding was determined by adding 80 Mg/ml ofhuman Fab anti-
Sm, normal human Fab, or normal human IgG at the time of
serum addition. Samples were tested in duplicate. The results are
shown as the average value of all mice in a group. Antibodies
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against KLH were measured using a similar assay; however, the
serum samples were diluted 1/50,000.
For inhibition experiments, a soluble reagent added to the
ELISA was arbitrarily considered to be inhibitory if there was a
reduction of 50% or more in O.D.
Western blots
RSm was affinity purified as described above. The RSm was
prepared for electrophoresis by boiling one volume ofantigen (2
mg/ml) with one volume of sample buffer containing 0-0625 M
Tris, 2% w/v sodium dodecyl sulphate (SDS), 5% 2-mercap-
toethanol v/v and 10% v/v glycerol. The diluted sample was
electrophoresed on a 3 5% polyacrylamide stacking gel and
12-5% polyacrylamide resolving slab gel in an electrode buffer
(0025 M Tris hydroxide, 0-192 M glycine and 1% w/v SDS).
Electrophoresis was performed at 200 for 2 5 hr at 40mA per gel
with constant current using a modification of the procedure
described by Laemmli (Laemmli, 1970). The separated polypep-
tides were transferred to nitrocellulose by electroblotting in
transfer buffer (150 mm glycine, 25 mm Tris hydroxide, 20%
methanol, pH 8 3) for 1 5 hr at 100. The nitrocellulose paper was
then blocked with a solution of PBS-5% BSA for 2 hr. Strips 6
mm wide were cut from the nitrocellulose paper and incubated
with sera diluted in blotting buffer (PBS, 0 85% Tween 80, 1%
BSA). The sera were used at dilutions at which they gave
comparable ODs by ELISA. Following incubation with the
sera, the strips were incubated with peroxidase labelled goat
anti-mouse IgG or rabbit anti-human IgG (Cappel Worth-
ington Biochemical, Malvern, PA, U.S.A.) diluted in blotting
buffer to 1/500 and 1/250, respectively. The bound antibodies
were visualized by adding the horseradish peroxidase colour
development reagent (Bio-Rad, Richmond, CA, U.S.A.), as
suggested by the supplier.
RESULTS
Sm responses of normal mice
We immunized normal mice with Sm to determine whether they
could produce anti-Sm. All normal strains tested produced anti-
Sm in response to challenge with RSm, but not in response to
KLH (Fig. 1). Anti-Sm levels in immunized mice showed
apparent strain-dependent variations, with B1O.A and B1O.D2
displaying particularly low levels of the antibody (Fig. 1).
Further examination of congenic BlO strains revealed low
responsiveness to Sm immunization of all mice of this back-
ground (Fig. 2). These results were confirmed in two additional
experiments. The observed differences in magnitude of anti-Sm
responses were not due to differential recognition of different
Igh allotypes by the biotinylated anti-mouse IgG reagent, as
there was no difference in the binding of the reagent to myeloma
proteins of the Igha and Ighb allotypes (data not shown).
Previous work from our laboratory demonstrated that all
strains could mount a T-cell proliferative response to RSm,
whereas only H-2f and H-2s strains displayed a similar response
to the mouse autoantigen, MSm (Bernard et al., 1985a, 1985b).
These findings could suggest enhanced antibody responsiveness
of H-2s and H-2f mice, especially if their T cells recognized
additional epitopes in Sm not seen by strains expressing other
H-2 alleles. The data in Fig. 3 indicate, however, that responses
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Figure 2. Mice with a BlO background respond poorly to RSm. H-2
congenic B10 mice and non-congenic C3H and MRL/+ mice were
immunized with RSm or KLH and tested for the presence of anti-Sm
and anti-KLH antibodies by ELISA. Samples were obtained from mice
12 weeks following their first immunization, and values represent mean
and standard error for groups of four to six mice.
ANTI- KLH
Figure 3. The ability to mount T-cell responses to MSm does not
determine generation of anti-RSm antibodies. Mice of the A strain
background were immunized with RSm or KLH and their sera were
tested for the presence of anti-RSm or anti-KLH antibodies by ELISA.
Samples were obtained from mice 12 weeks following their first
immunization and values represent the mean and standard error offour
to six mice. MRL/lpr* represents the anti-Sm ELISA value of a
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Figure 4. Specificity ofexperimentally induced anti-Sm antibodies. Individual 12 week sera from mice immunized with RSm were tested
for the presence of anti-Sm by ELISA in the absence or presence of 80 pg/ml ofhuman anti-Sm Fab or normal human Fab. The mean
OD value of four to six mice is reported. Standard errors were less than 10% of the means. MRL/ + * and MRL/ I pr* denote responses
of standard pools of spontaneously anti-Sm positive MRL/+ and MRL/ lpr sera, respectively.
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Figure 5. Immunoblot analysis of spontaneous anti-Sm. Sm proteins
were transferred to nitrocellulose strips, which were then probed with
sera at a dilution that had previously been demonstrated to yield a
standard and comparable ELISA reading. Lane 1, Human SLE anti-
Sm; Lane 2, Human SLE anti-RNP; Lane 3, MRL/lpr anti-Sm
negative; Lane 4, MRL/ I pr anti-Sm positive; Lane 5, MRL/ 1 pr anti-Sm
positive; Lane 6, MRL/ + anti-Sm positive.
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Figure 6. Experimentally induced anti-Sm from MRL and non-
autoimmune prone mice recognizes Sm proteins. Serum samples from
mice immunized with RSm were diluted to a concentration at which they
gave similar OD values by ELISA (1/100-1/640) and used to probe Sm
antigens by Western blot. Sera from mice immunized with KLH were
diluted to 1/100. Lane 1, SLE patient, anti-Sm positive; Lane 2, MRL/
Ipr spontaneous anti-Sm positive; Lane 3, MRL/+ spontaneous anti-
Sm positive; Lane 4, B6C3 immunized with KLH; Lane 5, B6C3
immunized with RSm; Lane 6, C3H immunized with KLH; Lane 7, C3H
immunized with RSm; Lane 8, C3H.SW immunized with KLH; Lane 9,
C3H.SW immunized with RSm; Lane 10, C3H.SW immunized with















congenic mice expressing other H-2 alleles [compare A.SW (H-
2S) and A.CA (H-2) to A.BY (H-2b]; a second experiment gave
the same result. Furthermore, expression of the H-2f and H-2s
alleles was not sufficient to overcome the low responsiveness of
the B10 background, since BIO.M (H-2f) and BlO.S (H-2s) failed
to generate a significant antibody response (Fig. 2).
Specificity of induced anti-Sm: inhibition by polyclonal human
anti-Sm
To determine whether induced antibodies to Sm recognized the
same regions ofSm as spontaneously occurring autoantibodies,
we compared their ability to compete for binding to Sm with
that ofanti-Sm IgG Fab fragments derived from the serum ofan
SLE patient (anti-Sm Fab). The human anti-Sm Fab effectively
inhibited the binding of spontaneous anti-Sm antibodies from
MRL/+ and MRL/lpr mice, whereas a normal human control
Fab preparation (NHu Fab) had no effect (Fig. 4). Likewise,
experimentally induced MRL/+ anti-Sm was strongly inhibited
by human anti-Sm Fab. In contrast to the results with MRL
sera, most mouse strains tested produced anti-Sm which was
inhibited weakly or not at all by the human anti-Sm. Of those
tested strains, only C3H and AKR generated anti-Sm anti-
bodies that were inhibited by the Fab anti-Sm, i.e. reduced
ELISA OD of > 50%. A lesser degree of inhibition was seen for
CBA. These results were confirmed using sera from multiple
time points and a minimum of five sera were used in each
determination.
Subclass of induced anti-Sm
Spontaneous anti-Sm antibodies from both MRL/lpr and
MRL/+ are predominantly of the IgG2a isotype, while the
IgG2b and IgG3 isotypes contribute to a lesser degree to total
anti-Sm antibodies and IgGI is the least prevalent IgG subclass
in this response (Eisenberg, Winfield & Cohen, 1982). In
contrast, MRL/ + mice immunized with RSm generate predom-
inantly IgGl anti-Sm antibodies (Shores et al., 1986). The
isotype distribution of experimentally induced anti-RSm and
anti-KLH antibodies from non-autoimmune mice was also
found to be mainly IgGl (not shown). As IgGI is generally a T-
cell dependent isotype, the data imply that the production of
experimental anti-Sm requires the collaboration of T cells, as
does the generation of spontaneous anti-Sm.
Western blot analysis of induced anti-Sm
The Sm antigen has been demonstrated to be a complex
composed of several different proteins (Lerner & Steitz, 1979,
1981; Reuter & Luhrmann, 1986; Eisenberg et al., 1987;
Brennan et al., 1988). The failure of Fab anti-Sm to inhibit the
binding of some induced anti-Sm antibodies suggested that
experimental anti-Sm might react with different determinants in
the Sm preparations. These could be additional epitopes on the
Sm proteins (termed D, B, and B') which are recognized by
spontaneous anti-Sm; Sm proteins not seen by spontaneous
anti-Sm; or contaminating non-Sm proteins.
To differentiate among these possibilities, the individual Sm
proteins were separated by SDS-polyacrylamide electrophore-
sis, transferred to nitrocellulose paper, and probed with specific
antisera. As shown in Fig. 5, when a human SLE anti-Sm
standard from the Centers for Disease Control (Atlanta, GA,
U.S.A.) was used to probe these blots, a 12,000 and a 25-26,000
MW protein could be detected; these proteins presumably
correspond to the B and D Sm proteins described by Steitz and
co-workers (Lerner & Steitz, 1979, 1981). In subsequent experi-
ments this pattern of reactivity was confirmed with sera from
other SLE patients with anti-Sm antibodies and with mouse
monoclonal anti-Sm antibodies. A similar pattern was detected
in the sera of both MRL/+ and MRL/lpr mice with sponta-
neous anti-Sm antibodies (Fig. 5). Approximately twenty-five
such sera were examined in this fashion and gave the same
result. In contrast, sera from an SLE patient and from MRL
mice lacking anti-Sm failed to detect these proteins.
We then compared the profile of proteins recognized by
experimentally induced anti-Sm antibodies to those recognized
by spontaneously generated anti-Sm antibodies from MRL
mice. In these experiments, the sera were all adjusted to a
concentration which gave a similar OD value by ELISA assay
(generally a 1/100-1/640 dilution). Control sera were obtained
from mice immunized with KLH and were used at a final
dilution of 1/100. As shown in Fig. 6, we found that sera from
mice immunized with RSm recognized D, B, and B', in a pattern
similar to that of spontaneous anti-Sm. The results shown are
representative of results obtained with over thirty samples of
serum from immunized mice.
DISCUSSION
The present study extends our previous findings concerning the
immunogenicity of purified Sm. Whereas spontaneous produc-
tion of anti-Sm is known to be strictly limited to MRL mice
(Eisenberg et al., 1978), rabbit Sm-immunized normal mice were
able to generate specific antibodies against Sm. Experimentally
induced antibodies, in both normal and MRL mice, were
generally reactive by immunoblot with the same Sm proteins
recognized by spontaneous anti-Sm. MRL anti-Sm, both
spontaneous and induced, was readily inhibited using standard
high titre SLE anti-Sm Fab fragments. By contrast, antibodies
induced in most normal strains were poorly inhibited.
It is of particular note that essentially all of the immunized
MRL/+ and normal mice developed anti-Sm, whereas only a
minority ofMRL/+ mice develop this specificity spontaneously
(Eisenberg et al., 1978; Brennan et al., 1988). Importantly, in
MRL/+ as well as in some normal mice, the specificity of the
experimentally-induced antibody was similar to that of the
spontaneous antibody, as judged by competitive binding experi-
ments and by immunoblots. It appears, therefore, that the
potential to make bona fide anti-Sm is present in all MRL/+
mice, despite their variability in spontaneous anti-Sm produc-
tion, and indeed is present in normal mice as well. It is of note
that, ofthe eleven normal strains examined, only C3H and AKR
produced anti-Sm the binding of which was strongly inhibited
by the human anti-Sm. It is likely that the ability to produce
anti-Sm which recognizes epitopes also seen by SLE anti-Sm
may be the result of genes present in these but not in the other
inbred strains. MHC-linked genes are not likely to be respon-
sible, as B6C3 (which expresses H-2k) does not produce
antibody which recognizes such determinants. Neither is it likely
to be due to allelic genes linked to Igh, as the 'responder' strains
do not share a common immunoglobulin heavy-chain allotype
(Ig-li for MRL and C3H, Ig-ld for AKR.) It may be significant
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that both C3H and AKR were among the strains which
contributed to the MRL genome, and thus it is possible that the
ability of MRL to respond to certain epitopes on Sm is due to
genes derived from these strains. The influence of other
background genes on the amount of anti-Sm produced is
evidenced by the relatively poor response of B10 mice to Sm.
It is perhaps surprising that all strains of mice tested were
able to respond to Sm. The low B-cell precursor frequency for
this specificity probably explains the need for repeated immuni-
zation (Cohen et al., 1985), and is consistent with a recent report
in which in vitro LPS stimulation of normal and MRL spleen
cells gave rise to anti-RNP but not to anti-Sm (Brennan et al.,
1988). The universal ability to respond to Sm immunization in
mice may be due to the fact that antigen in adjuvant potently
stimulates the immune system and provides a signal for
antibody production which is normally absent. For instance,
immunization with Sm may augment the normal pathway of
anti-Sm production by expanding existing Sm-reactive helper T-
cell clones to collaborate productively with B cells.
The reproducible induction ofanti-Sm by immunization is in
contrast to the spontaneous development of this specificity in
only a minority of MRL mice. We have hypothesized that the
bimodal distribution of spontaneous anti-Sm in MRL mice
results from a stochastic event (or events) which occurs in
somatic cells ofcertain mice (Eisenberg et al., 1987). A candidate
event is the emergence in the T-cell repertoire of clones with a
special efficiency in recognizing the Sm antigen or in collaborat-
ing with B cells. By hyperimmunizing, we may be driving the
clonal expansion of such T cells, or stimulating sufficient
numbers ofcross-reactive T cells which are capable ofproviding
the needed help for anti-Sm production. Xenogeneic Sm may be
a particularly potent immunogen because ofadditional epitopes
available for T-cell recognition. Pertinent in this regard, are
recent studies reporting the generation in normal mice of
monoclonal antibodies reactive to components of Sm upon
immunization with Sm purified from human cells, and in rabbits
after challenge with goat antigen (Reuter & Luhrmann, 1986;
Ishaq & Ali, 1984).
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